close 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 73% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade

LLY

1,027.92

+1.8%↑

JNJ

195.38

+0.54%↑

ABBV

235.65

+1.28%↑

UNH

333.89

-1.67%↓

AZN

88.82

+1.64%↑

LLY

1,027.92

+1.8%↑

JNJ

195.38

+0.54%↑

ABBV

235.65

+1.28%↑

UNH

333.89

-1.67%↓

AZN

88.82

+1.64%↑

LLY

1,027.92

+1.8%↑

JNJ

195.38

+0.54%↑

ABBV

235.65

+1.28%↑

UNH

333.89

-1.67%↓

AZN

88.82

+1.64%↑

LLY

1,027.92

+1.8%↑

JNJ

195.38

+0.54%↑

ABBV

235.65

+1.28%↑

UNH

333.89

-1.67%↓

AZN

88.82

+1.64%↑

LLY

1,027.92

+1.8%↑

JNJ

195.38

+0.54%↑

ABBV

235.65

+1.28%↑

UNH

333.89

-1.67%↓

AZN

88.82

+1.64%↑

Kodu・Aktsiate loetelu・Madrigal Pharmaceuticals Inc
Search

Madrigal Pharmaceuticals Inc

Avatud

SektorTervishoid

517.51 -1.85

Tugev "osta" hinnang

Hinna uuendus 13. nov 2025, 19:57 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

513.42

Max

531.26

Põhinäitajad

By Trading Economics

Sissetulek

-72M

-114M

Müük

74M

287M

Aktsiakasum

-4.956

Kasumimarginaal

-39.75

Töötajad

528

EBITDA

-75M

-114M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

-2.98% downside

Turustatistika

By TradingEconomics

Turukapital

2.1B

11B

Eelmine avamishind

519.36

Eelmine sulgemishind

517.51

Uudiste sentiment

By Acuity

34%

66%

107 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

263.2 / 277.1 Toetus ja vastupanu

Madrigal Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. nov 2025, 21:55 UTC

Tulu

Xero Beats 1st Half Profit Expectations Despite Melio Margin Hit

DJ

Loe

12. nov 2025, 21:34 UTC

Tulu

Cisco Systems Boosts Fiscal Year Outlook as 1Q Profit, Revenue Rise

DJ

Loe

12. nov 2025, 23:44 UTC

Market Talk

Nikkei May Trade in Range Amid Caution Over U.S. Econ -- Market Talk

DJ

Loe

12. nov 2025, 23:38 UTC

Market Talk

Gold Steady Ahead of Expected End to U.S. Government Shutdown -- Market Talk

DJ

Loe

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Net Profit Largely Met FactSet-Compiled Consensus

DJ

Loe

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Net KRW538.50B Vs. Net KRW554.56B >000810.SE

DJ

Loe

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Oper Pft KRW664.06B Vs. Pft KRW717.46B >000810.SE

DJ

Loe

12. nov 2025, 23:13 UTC

Tulu

Samsung Fire & Marine Insurance 3Q Rev KRW5.732T Vs. KRW5.326T >000810.SE

DJ

Loe

12. nov 2025, 22:30 UTC

Market Talk
Tulu

Firefly Aerospace Sets Plan for Next Launch After Explosion -- Market Talk

DJ

Loe

12. nov 2025, 22:18 UTC

Tulu

Cisco Systems Boosts Outlook on AI-Driven Demand -- Update

DJ

Loe

12. nov 2025, 22:12 UTC

Market Talk

Bank of Canada Rate Hikes Could Start in 2H 2026 -- Market Talk

DJ

Loe

12. nov 2025, 22:05 UTC

Tulu

Pan American Silver: Campbell Succeeded Steve Busby >PAAS

DJ

Loe

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver Named Scott Campbell as Operating Chief on Oct. 20

DJ

Loe

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver 3Q Adj EPS 48c >PAAS

DJ

Loe

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver 3Q Rev $884.4M >PAAS

DJ

Loe

12. nov 2025, 22:04 UTC

Tulu

Pan American Silver 3Q EPS 45c >PAAS

DJ

Loe

12. nov 2025, 22:03 UTC

Tulu

Manulife Financial: 3Q Book Value Per Common Shr C$26.07 >MFC.T

DJ

Loe

12. nov 2025, 22:02 UTC

Tulu

Manulife Financial 3Q Net C$1.8B >MFC

DJ

Loe

12. nov 2025, 22:02 UTC

Tulu

Manulife Financial 3Q Adj EPS C$1.16 >MFC

DJ

Loe

12. nov 2025, 22:02 UTC

Tulu

Manulife Financial 3Q EPS C$1.02 >MFC

DJ

Loe

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel: Sale Strengthens Focus on Own Growth Investments

DJ

Loe

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Says Deal Subject to Indian Regulatory Approvals

DJ

Loe

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Estimates Net Profit After Tax on Sale of A$70 Million

DJ

Loe

12. nov 2025, 21:53 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Expects Net Proceeds After Taxes, Fees of A$179 Million in 2H FY26

DJ

Loe

12. nov 2025, 21:52 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel: Tata BlueScope Steel JV a Provider of Coated, Painted Steel Products in India

DJ

Loe

12. nov 2025, 21:51 UTC

Omandamised, ülevõtmised, äriostud

BlueScope Steel Agrees to Sell 50% Stake in Tata BlueScope Steel Joint Venture to Tata Steel

DJ

Loe

12. nov 2025, 21:50 UTC

Market Talk
Tulu

Basic Materials Roundup: Market Talk

DJ

Loe

12. nov 2025, 21:49 UTC

Tulu

Cisco Stock Climbs as Earnings Beat Expectations Amid Strong AI Demand -- Barrons.com

DJ

Loe

12. nov 2025, 21:48 UTC

Tulu

If Investors Like Rocket Lab Stock, They Should Love Firefly Shares. -- Barrons.com

DJ

Loe

12. nov 2025, 21:40 UTC

Tulu

Xero Beats 1H Profit Expectations Despite Melio Margin Hit

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Madrigal Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

-2.98% langus

12 kuu keskmine prognoos

Keskmine 525.38 USD  -2.98%

Kõrge 590 USD

Madal 392 USD

Põhineb 16 Wall Streeti analüütiku instrumendi Madrigal Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

16 ratings

15

Osta

1

Hoia

0

Müü

Põhineb 16 analüütiku instrumendi Madrigal Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

263.2 / 277.1Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Bearish events outweigh bullish events.

Keskpikk perspektiiv

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Pikk perspektiiv

Neutral Evidence

The bullish and bearish events are balanced.

Sentiment

By Acuity

107 / 374 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,027.92

↑ +1.8%

JNJ

Johnson and Johnson

195.38

↑ +0.54%

ABBV

AbbVie Inc

235.65

↑ +1.28%

UNH

UnitedHealth Group Inc

333.89

↓-1.67%

AZN

AstraZeneca PLC ADR

88.82

↑ +1.64%
help-icon Live chat